Pertussis in adolescents

Advances in Therapy

Volumn 24, Issue 2, 2007, Pages 353-361

  Leung, Alexander K C ^a,c   Robson, William Lane M ^a   Davies, H Dele ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NONE   (Canada)

Author keywords

Adolescent; Pertussis; Universal immunization

Indexed keywords

ADENYLATE CYCLASE TOXIN; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOTOXIN; DERMONECROTIC TOXIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; HEMAGGLUTININ; LIPOPOLYSACCHARIDE ENDOTOXIN; MACROLIDE; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ANAPHYLAXIS; ARTICLE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; CHILL; CLINICAL TRIAL; COUGHING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE SWELLING; IRRITABILITY; MUSCLE HYPOTONIA; NORTH AMERICA; OPTIMAL DRUG DOSE; PAIN; PATHOLOGICAL CRYING; PERTUSSIS; PNEUMONIA; POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SERODIAGNOSIS; SIDE EFFECT; SINGLE DRUG DOSE; UNITED STATES;

EID: 34250843159     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849904     Document Type: Article

References (40)

1. Aguas R, Goncalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis. 2006;6:112-117.
2. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367:1926-1936.
3. Tan T, Trindale E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24:S10-S18.
4. Greenberg DP. Pertussis in adolescents: increasing incidence brings attention to the need for booster immunization of adolescents. Pediatr Infect Dis J. 2005;24:721-728.
5. Long SS, Edwards KM. Bordetella pertussis (pertussis) and other species. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingstone; 2003:880-888.
6. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24:S25-S34.
7. Franco E, Giambi C, Ialacci R, Maurici M. Pertussis vaccination for adolescents and adults. Expert Opin Biol Ther. 2004;4:1669-1676.
8. Steele RW. Pertussis: is eradication achievable? Pediatr Ann. 2004;33:525-534.
9. Preston A. Bordetella pertussis: the intersection of genomics and pathobiology. CMAJ. 2005;173:55-62.
10. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J. 2005;24:S75-S82.
11. Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agent for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep. 2005;54(RR-14):1-16.
12. Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005;24:S127-S133.
13. Centers for Disease Control and Prevention. Notifiable diseases/deaths in selected cities weekly information. MMWR Morb Mortal Wkly Rep. 2004;53:1213-1221.
14. Centers for Disease Control and Prevention. Resurgence of pertussis: United States, 1993. MMWR Morb Mortal Wkly Rep. 1993;42:952-960.
15. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51:73-76.
16. Rothstein E, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J. 2005;24:S44-S47.
17. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185:1448-1453.
18. Middleman AB, Rosenthal SL, Rickert VI, Neinstein L, Fishbein DB, D'Angelo L. Adolescent immunizations: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;38:321-327.
19. Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24:S58-S61.
20. Mooi FR, van Loo IHM, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis. 2001;73(suppl 3):526-528.
21. Hewlett EL, Edwards KM. Pertussis: not just for kids. N Engl J Med. 2005;352:1215-1222.
22. Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S. Diagnosis and management of pertussis. CMAJ. 2005;172:509-515.
23. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA. 1995;273:1044-1046.
24. Gordon M, Davies HD, Gold R. Clinical and microbiologic features of children presenting with pertussis to a Canadian pediatric hospital during an eleven-year period. Pediatr Infect Dis J. 1994;13:617-622.
25. Munoz FM. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Seiniti Pediatr Infect Dis. 2006;17:14-19.
26. de Melker HE, Versteegh FGA, Conyn-van Spaendonck MAE, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol. 2000;38:800-806.
27. Srinivasan R, Yeo TH. Are newer macrolides effective in eradicating carriage of pertussis? Arch Dis Child. 2005;90:322-324.
28. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2005;1:CD004404.
29. Pichichero ME, Hoeger WJ, Casey JR. Azithromycin for the treatment of pertussis. Pediatr Infect Dis J. 2003;22:847-849.
30. Langley JM, Halperin SA, Boucher FD, Smith B, and the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC). Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics. 2004;114:e96.
31. Frydenberg A, Starr M. Pertussis: presentation, investigation and management. Aust Fam Physician. 2004;33:317-319.
32. Centers for Disease Control and Prevention. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin - Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep. 1999;48:1117-1120.
33. Tan T, Halperin S, Cherry JD, et al. Pertussis immunization in the Global Pertussis Initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J. 2005;24:S83-S86.
34. National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
35. WHO. Pertussis vaccines - WHO position paper. Wkly Epidemiol Rec. 2005;80:31-39.
36. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003-2014.
37. Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2000(2):CD001478.
38. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117:1084-1093.
39. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117:965-978.
40. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (AGP). MMWR Recomm Rep. 2006;55(RR-3):1-34.